Gracell Biotechnologies Past Earnings Performance
Past criteria checks 0/6
Gracell Biotechnologies's earnings have been declining at an average annual rate of -28.6%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 14.5% per year.
Key information
-28.6%
Earnings growth rate
0.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 14.5% |
| Return on equity | -30.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
Feb 21Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform
Sep 22Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02
Aug 15Gracell Biotechnologies rallies after naming new chief medical officer
Aug 01Gracell names Dr. Samuel Zhang as Chief Business Officer
Jul 19Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Nov 26Gracell ends IPO quiet period with favorable views from analysts
Feb 02Revenue & Expenses BreakdownBeta
How Gracell Biotechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -497 | 134 | 445 |
| 30 Jun 23 | 0 | -601 | 139 | 488 |
| 31 Mar 23 | 0 | -601 | 130 | 501 |
| 31 Dec 22 | 0 | -608 | 139 | 485 |
| 30 Sep 22 | 0 | -605 | 135 | 480 |
| 30 Jun 22 | 0 | -563 | 142 | 435 |
| 31 Mar 22 | 0 | -513 | 143 | 383 |
| 31 Dec 21 | 0 | -454 | 137 | 327 |
| 30 Sep 21 | 0 | -425 | 130 | 280 |
| 30 Jun 21 | 0 | -365 | 95 | 231 |
| 31 Mar 21 | 0 | -332 | 72 | 207 |
| 31 Dec 20 | 0 | -275 | 46 | 169 |
| 30 Sep 20 | 0 | -228 | 29 | 146 |
| 31 Dec 19 | 0 | -201 | 27 | 119 |
Quality Earnings: GRCL is currently unprofitable.
Growing Profit Margin: GRCL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRCL is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare GRCL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRCL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Return on Equity
High ROE: GRCL has a negative Return on Equity (-30.66%), as it is currently unprofitable.